A Study of LY3025876 in Participants With Diabetes

NCT01870297 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug LY3025876 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 72 people

Who can join Ages 21–70 · all sexes

Timeline Started 2013-06 · est. completion 2014-12

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT01870297 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).

Treatments tested

LY3025876 Drug

Administered SQ
Placebo Drug

Administered SQ
Liraglutide Drug

Administered SQ

Main thing measured	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01870297 ↗